Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Tolerability and pulmonary pharmacodynamic effects during treatment initiation of once-daily oral fingolimod in subjects with moderate asthma

Boulton, C and David, OJ and Meiser, K and Schmouder, R (2013) Tolerability and pulmonary pharmacodynamic effects during treatment initiation of once-daily oral fingolimod in subjects with moderate asthma. Clinical Pharmacology in Drug Development. pp. 2-10.

Abstract

Fingolimod, a first-in-class sphingosine 1-phosphate receptor modulator, is the first approved oral therapy for relapsing multiple sclerosis (MS). While treatment initiation of clinical dose of fingolimod (0.5 mg) does not affect pulmonary function, supra-therapeutic doses (>5.0 mg) increased airway resistance. The aim of this double-blind, placebocontrolled, parallel group, 10-day study was to measure the effect of fingolimod on pulmonary function in otherwise healthy patients with moderate asthma. Subjects (n 1/4 36) were randomized into four cohorts that received either fingolimod 0.5, 1.25, 2.5 mg, or placebo once daily for 10 days. Subjects in placebo and fingolimod 0.5 mg groups did not differ in FEV<sub>1</sub>AUEC<sub>0-6 h</sub>, FEF<sub>25-75%</sub> AUEC<sub>0-6</sub> h, or in short-acting beta (beta) 2 agonists (SABA, rescue bronchodilator) use. Subjects on higher doses of fingolimod showed a mild reduction in FEV<sub>1</sub>AUEC<sub>0-6 h</sub> and FEF<sub>25-75%</sub>AUEC<sub>0-6</sub> h and a significant sixfold increase in SABA use versus placebo. One subject had moderately severe, acute exacerbation of asthma after receiving the first dose of fingolimod 1.25 mg that quickly responded to inhaled SABA. The observed safety profile was consistent with previous reports. These results provide reassurance that moderately asthmatic MS individuals can start on fingolimod 0.5 mg therapy with minimal effects on pulmonary function and SABA use. The Author(s) 2013

Item Type: Article
Additional Information: pubid: 237 nvp_institute: NIBR contributor_address: (Boulton) Novartis Horsham Research Centre, Horsham, West Sussex, United Kingdom (David) Novartis Institutes for Biomedical Research, Basel, Switzerland (Meiser) Novartis Pharma AG, Basel, Switzerland (Schmouder) Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
Date Deposited: 13 Oct 2015 13:12
Last Modified: 13 Oct 2015 13:12
URI: https://oak.novartis.com/id/eprint/22043

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.